These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 20070285)
1. Estradiol limits viral replication following intravaginal immunization leading to diminished mucosal IgG response and non-sterile protection against genital herpes challenge. Gillgrass A; Chege D; Bhavanam S; Kaushic C Am J Reprod Immunol; 2010 Apr; 63(4):299-309. PubMed ID: 20070285 [TBL] [Abstract][Full Text] [Related]
2. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. Gillgrass AE; Tang VA; Towarnicki KM; Rosenthal KL; Kaushic C J Virol; 2005 Mar; 79(5):3117-26. PubMed ID: 15709031 [TBL] [Abstract][Full Text] [Related]
3. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Kwant A; Rosenthal KL Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061 [TBL] [Abstract][Full Text] [Related]
4. Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Bhavanam S; Snider DP; Kaushic C Vaccine; 2008 Nov; 26(48):6165-72. PubMed ID: 18804503 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Milligan GN; Dudley-McClain KL; Chu CF; Young CG Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519 [TBL] [Abstract][Full Text] [Related]
6. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530 [TBL] [Abstract][Full Text] [Related]
7. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Gallichan WS; Rosenthal KL Virology; 1996 Oct; 224(2):487-97. PubMed ID: 8874509 [TBL] [Abstract][Full Text] [Related]
8. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Tengvall S; O'Hagan D; Harandi AM Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020 [TBL] [Abstract][Full Text] [Related]
9. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. Tengvall S; Harandi AM J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349 [TBL] [Abstract][Full Text] [Related]
10. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672 [TBL] [Abstract][Full Text] [Related]
11. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection. Gill N; Rosenthal KL; Ashkar AA J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447 [TBL] [Abstract][Full Text] [Related]
12. Adaptive immune responses fail to provide protection against genital HSV-2 infection in the absence of IL-15. Gill N; Ashkar AA Eur J Immunol; 2007 Sep; 37(9):2529-38. PubMed ID: 17668897 [TBL] [Abstract][Full Text] [Related]
13. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Wizel B; Persson J; Thörn K; Nagy E; Harandi AM Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292 [TBL] [Abstract][Full Text] [Related]
14. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270 [TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Del Campo J; Lindqvist M; Cuello M; Bäckström M; Cabrerra O; Persson J; Perez O; Harandi AM Vaccine; 2010 Feb; 28(5):1193-200. PubMed ID: 19945418 [TBL] [Abstract][Full Text] [Related]
16. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. Milligan GN; Bernstein DI; Bourne N J Immunol; 1998 Jun; 160(12):6093-100. PubMed ID: 9637526 [TBL] [Abstract][Full Text] [Related]
17. Maternal immunization with a herpes simplex virus type 2 replication-defective virus reduces visceral dissemination but not lethal encephalitis in newborn mice after oral challenge. Evans IA; Jones CA J Infect Dis; 2002 Jun; 185(11):1550-60. PubMed ID: 12023760 [TBL] [Abstract][Full Text] [Related]
18. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Morrison LA; Da Costa XJ; Knipe DM Virology; 1998 Mar; 243(1):178-87. PubMed ID: 9527927 [TBL] [Abstract][Full Text] [Related]
19. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Sherwood JK; Zeitlin L; Whaley KJ; Cone RA; Saltzman M Nat Biotechnol; 1996 Apr; 14(4):468-71. PubMed ID: 9630921 [TBL] [Abstract][Full Text] [Related]
20. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Hendrickson BA; Guo J; Brown I; Dennis K; Marcellino D; Hetzel J; Herold BC Virology; 2000 May; 271(1):155-62. PubMed ID: 10814580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]